Dr. B, a New York-based telehealth company that makes healthcare services available regardless of a patient’s ability to pay, raised $8M in funding.
Backers included Lerer Hippeau, Founders Fund and other investors.
The company intends to use the funds to expand access to everyday prescriptions through its new “Visitless Prescription” service.
Led by CEO Cyrus Massoumi, Dr. B provides a telehealth service that allows patients to access a low-cost, online doctor consultation and then send resulting prescriptions to any pharmacy—all without leaving home. Patients complete an online health assessment. A board-certified physician then reviews the patient’s medical record and provides the patient with a prescription, if appropriate. Dr. B patients can have the prescription filled at the pharmacy of their choice. The telehealth service is launching first with Paxlovid and molnupiravir (Lagevrio) — the two at-home oral Covid-19 antivirals authorized for use by the FDA — to provide the most convenient way to treat Covid amid a surge in cases across the United States. The new prescription service is currently available in Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, Wisconsin and Wyoming, with additional states being added soon.
Dr. B is also planning to soon offer Visitless Prescriptions for a wide range of everyday medications, from heart health to dermatology and reproductive care.
FinSMEs
16/08/2022
The company raised $8 million for the new telehealth platform, including from Lerer Hippeau, Founders Fund and other investors that support Dr. B’s mission to make healthcare more equitable. “Dr. B’s mission to make healthcare more equitable and affordable, starting with Covid antivirals, will be critical to progressing the pandemic into an endemic state,” said Ben Lerer, Managing Partner at Lerer Hippeau